This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2017 Nov 14;136(20):1892-1894.

doi: 10.1161/CIRCULATIONAHA.117.030989.

Closing the Remaining Evidence Gap: Randomized Controlled Trial Data to Support Statin Therapy for Low-Density Lipoprotein ≥190 mg/dL

Karol E Watson^{1

2}, Gregg C Fonarow^{3

4}

Affiliations

Affiliations

¹ Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (UCLA) (K.E.W., G.C.F.). kwatson@mednet.ucla.edu.
² Barbra Streisand-UCLA Women's Heart Health Program (K.E.W.).
³ Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (UCLA) (K.E.W., G.C.F.).
⁴ Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center (G.C.F.).

PMID: 29133529
DOI: 10.1161/CIRCULATIONAHA.117.030989

Editorial

Closing the Remaining Evidence Gap: Randomized Controlled Trial Data to Support Statin Therapy for Low-Density Lipoprotein ≥190 mg/dL

Karol E Watson et al. Circulation. 2017.

. 2017 Nov 14;136(20):1892-1894.

doi: 10.1161/CIRCULATIONAHA.117.030989.

Authors

Karol E Watson^{1

2}, Gregg C Fonarow^{3

4}

Affiliations

¹ Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (UCLA) (K.E.W., G.C.F.). kwatson@mednet.ucla.edu.
² Barbra Streisand-UCLA Women's Heart Health Program (K.E.W.).
³ Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles (UCLA) (K.E.W., G.C.F.).
⁴ Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center (G.C.F.).

PMID: 29133529
DOI: 10.1161/CIRCULATIONAHA.117.030989

No abstract available

Keywords: Editorials; cholesterol; guidelines; statins.

PubMed Disclaimer

Comment on

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK. Vallejo-Vaz AJ, et al. Circulation. 2017 Nov 14;136(20):1878-1891. doi: 10.1161/CIRCULATIONAHA.117.027966. Epub 2017 Sep 6. Circulation. 2017. PMID: 28877913 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal